Each film coated tablet contains:
Active ingredient:
Clopidogrel | 75 mg |
Prevention of atherothrombotic
Myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7days until less than 6 months), or established peripheral arterial disease.
Acute coronary syndrome:
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), included patients who had undergone coronary intervention, in combination with acetylsalicylic acid.
ST-segment elevation acute myocardial infarction, in combination with acetylsalicylic acid in thrombolytic therapy
In patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA), and who have a low bleeding risk, clopidogrel is indicated in combination with acetylsalicylic acid for the prevention of atherothrombotic and thromboembolic events, including stroke.
POSOLOGY AND METHOD OF ADMINISTRATION
Method of administration:
CLOPALVIX for oral use, once a day, without regard to meals.
Posology
Adults and elderly: Dose 75 mg/time/day
Paediatric population: There is no experience of using this drug in children. It is not recommended using this drug in children
In patients suffering from acute coronary syndrome:
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): Clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day with acetylsalicylic acid 75 mg-325 mg daily. Acetylsalicylic acid less than 100 mg is recommended.
Patient with acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300-mg loading dose in combination with acetylsalicylic acid and with or without thrombolytics. For patients over 75 years of age, a daily dose of 75 mg. Treatment is continued for at least four weeks.
In patients with atrial fibrillation: Clopidogrel should be given as a single daily dose of 75 mg, then continue in combination with 75-100 mg acetylsalicylic acid daily.
CONTRAINDICATIONS
Hypersensitivity to clopidogrel or to any ingredient in the drug product
Severe hepatic impairment
Active pathological bleeding such as peptic ulcer or intracranial haemorrhage or any other condition that causes severe bleeding.
Breast-feeding
WARNINGS AND PRECAUTIONS
In patients with acute myocardial infarction, clopidogrel therapy should not be initiated during the first few days after myocardial infarction.
Clopidogrel prolongs bleeding time and therefore should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or other pathological conditions (particularly gastrointestinal and intraocular).
Clopidogrel is used with caution in patients with potentially bleeding lesions (such as ulcers).
If the patient is to undergo surgery and antiplatelet effect is temporarily not desirable, clopidogrel should be discontinued 7 days prior to surgery.
Therapeutic experience with clopidogrel is limited in patients with renal impairment and hepatic impairment. Therefore, clopidogrel should be used with caution in these patients.
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel, the drug should be discontinued when bleeding occurs and that they should report any unusual bleeding to their physician. Patients should inform physicians and dentists hat they are taking clopidogrel before any surgery is scheduled and before any new medicinal product is taken.
Shelf-life
36 months from the manufacturing date. Do not use after the expiry date
Box of 1 blister x 14 film-coated tablets.
Box of 5 blisters x 14 film-coated tablets.